Hoth Therapeutics Rises On FDA Accepting IND For Its HT-001 Therapeutic
Shares of Hoth Therapeutics, Inc. (HOTH) are rising more than 100% Thursday morning after the company said the FDA accepted Investigational New Drug (IND) application for the company’s HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung […]
Read more